Ignet

Gene Information

Gene symbol: VTCN1

Gene name: V-set domain containing T cell activation inhibitor 1

HGNC ID: 28873

Synonyms: B7-H4, FLJ22418, B7S1, B7X, B7H4

Related Genes

#	Gene Symbol	Number of hits
1	CD274	1 hits
2	CD276	1 hits
3	CD40	1 hits
4	CD8A	1 hits
5	CEACAM6	1 hits
6	HHLA2	1 hits
7	INDO	1 hits
8	LGALS1	1 hits
9	LGALS3	1 hits
10	PDCD1	1 hits
11	PDCD1LG2	1 hits
12	S100A7	1 hits
13	SP2	1 hits
14	SPDEF	1 hits
15	TLR1	1 hits

Related Sentences

#	PMID	Sentence
1	19763888	Further, we have identified certain PDEF-induced proteins including CEACAM6, B7-H4, and S100A7 as additional candidate breast tumor antigens.
2	21717068	The number of T-bet(+) TILs correlates with better survival of esophageal cancer patients.
3	21717068	Using well-defined mouse models, we have further shown that T-bet and Eomes are both required for the adaptive anti-tumor immunity by regulating T-cell trafficking into the tumor tissue and their effector functions inside the tumor microenvironment.
4	21717068	In order to gain further insight into the tumor immune microenvironment in the upper GI cancer, we have also studied expression levels of co-inhibitory molecules such as B7-H1/PD-L1 and B7-H4 in tissue specimens of esophageal and gastric cancers.
5	21717068	The number of CD3(+) and CD8(+) TILs correlates inversely with expression levels of B7-H4 in samples from esophageal cancer, supporting a role of active immune suppression by inhibitory B7 molecules in the tumor microenvironment.
6	21717068	In addition, TILs show functional exhaustion and express high levels of PD-1 and Tim-3.
7	21717068	Future tumor vaccine design should combine blockade of B7 inhibitory molecules and enhancement of T-bet and Eomes levels within the tumor microenvironment.
8	21717068	The number of T-bet(+) TILs correlates with better survival of esophageal cancer patients.
9	21717068	Using well-defined mouse models, we have further shown that T-bet and Eomes are both required for the adaptive anti-tumor immunity by regulating T-cell trafficking into the tumor tissue and their effector functions inside the tumor microenvironment.
10	21717068	In order to gain further insight into the tumor immune microenvironment in the upper GI cancer, we have also studied expression levels of co-inhibitory molecules such as B7-H1/PD-L1 and B7-H4 in tissue specimens of esophageal and gastric cancers.
11	21717068	The number of CD3(+) and CD8(+) TILs correlates inversely with expression levels of B7-H4 in samples from esophageal cancer, supporting a role of active immune suppression by inhibitory B7 molecules in the tumor microenvironment.
12	21717068	In addition, TILs show functional exhaustion and express high levels of PD-1 and Tim-3.
13	21717068	Future tumor vaccine design should combine blockade of B7 inhibitory molecules and enhancement of T-bet and Eomes levels within the tumor microenvironment.
14	23716685	HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function.
15	23716685	Here we describe HERV-H LTR-associating protein 2 (HHLA2) as a member of the B7 family that shares 10-18% amino acid identity and 23-33% similarity to other human B7 proteins and phylogenetically forms a subfamily with B7x and B7-H3 within the family.
16	23716685	HHLA2 is expressed in humans but not in mice, which is unique within the B7 and CD28 families.
17	23716685	HHLA2 does not interact with other known members of the CD28 family or the B7 family, but does bind a putative receptor that is constitutively expressed not only on resting and activated CD4 and CD8 T cells but also on antigen-presenting cells.
18	23716685	HHLA2 inhibits proliferation of both CD4 and CD8 T cells in the presence of T-cell receptor signaling.
19	23716685	In addition, HHLA2 significantly reduces cytokine production by T cells including IFN-γ, TNF-α, IL-5, IL-10, IL-13, IL-17A, and IL-22.
20	23716685	Thus, we have identified a unique B7 pathway that is able to inhibit human CD4 and CD8 T-cell proliferation and cytokine production.
21	24314141	Inhibition of mouse SP2/0 myeloma cell growth by the B7-H4 protein vaccine.
22	24658839	In an attempt to shed more light on the immunosuppressive environment in uterine tumors, we analyzed the presence of PD-L1, PDL2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galectin- 1, galectin-3, arginase-1 activity and myeloid-derived suppressor cell (MDSC) infiltration.
23	24658839	IDO, PD-L1, PD-L2 and B7-H4 were analyzed by immunohistochemistry.
24	24658839	For PD-L1 and B7-H4, we found high expression in 92 and 90 % of endometrial cancers, respectively, and in 100 and 92 % of the sarcomas.
25	24658839	These results indicate that the PD-1/PD-L1 interaction and B7-H4 could be possible targets for immune intervention in uterine cancer patients as well as mediation of MDSC function.
26	24658839	In an attempt to shed more light on the immunosuppressive environment in uterine tumors, we analyzed the presence of PD-L1, PDL2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galectin- 1, galectin-3, arginase-1 activity and myeloid-derived suppressor cell (MDSC) infiltration.
27	24658839	IDO, PD-L1, PD-L2 and B7-H4 were analyzed by immunohistochemistry.
28	24658839	For PD-L1 and B7-H4, we found high expression in 92 and 90 % of endometrial cancers, respectively, and in 100 and 92 % of the sarcomas.
29	24658839	These results indicate that the PD-1/PD-L1 interaction and B7-H4 could be possible targets for immune intervention in uterine cancer patients as well as mediation of MDSC function.
30	24658839	In an attempt to shed more light on the immunosuppressive environment in uterine tumors, we analyzed the presence of PD-L1, PDL2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galectin- 1, galectin-3, arginase-1 activity and myeloid-derived suppressor cell (MDSC) infiltration.
31	24658839	IDO, PD-L1, PD-L2 and B7-H4 were analyzed by immunohistochemistry.
32	24658839	For PD-L1 and B7-H4, we found high expression in 92 and 90 % of endometrial cancers, respectively, and in 100 and 92 % of the sarcomas.
33	24658839	These results indicate that the PD-1/PD-L1 interaction and B7-H4 could be possible targets for immune intervention in uterine cancer patients as well as mediation of MDSC function.
34	24658839	In an attempt to shed more light on the immunosuppressive environment in uterine tumors, we analyzed the presence of PD-L1, PDL2, B7-H4, indoleamine 2,3-dioxygenase (IDO), galectin- 1, galectin-3, arginase-1 activity and myeloid-derived suppressor cell (MDSC) infiltration.
35	24658839	IDO, PD-L1, PD-L2 and B7-H4 were analyzed by immunohistochemistry.
36	24658839	For PD-L1 and B7-H4, we found high expression in 92 and 90 % of endometrial cancers, respectively, and in 100 and 92 % of the sarcomas.
37	24658839	These results indicate that the PD-1/PD-L1 interaction and B7-H4 could be possible targets for immune intervention in uterine cancer patients as well as mediation of MDSC function.
38	25728020	This delayed response to innate immune agonists resulted in the reduced production of pro-inflammatory and antiviral cytokines and chemokines including TNFα, IL-6, IL-1β, IFNα, IFNγ, CCL2, and CCL7.
39	25728020	PBMCs from old subjects also had a lower frequency of CD40+ monocytes, impaired up-regulation of PD-L1 on monocytes and T cells, and increased expression of PD-L2 and B7-H4 on B cells.